CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
19-962/S-013

Final Printed Labeling
Date of Submission: January 11, 2001
Date of Review: January 19, 2001
Applicant Name: AstraZeneca
Product Name: Toprol-XL (metoprolol succinate) 25, 50, 100 and 200 mg Tablets

Evaluation:
This submission provides for final printed labeling, revised in accordance with our July 10, 2000 approvable letter and subsequent negotiations at a meeting held on October 23, 2000 between AstraZeneca and the Agency. Draft labeling that was acceptable to the Agency was submitted on December 20, 2000 by AstraZeneca.

The final printed labeling is exactly like the labeling submitted on December 20, 2000 except that under the, “Clinical Endpoints in the MERIT-HF Study” table, “Sudden Death” and “Death Due to worsening heart failure” are indented under, “Cardiovascular mortality” as we requested in a telephone communication.

There were no other changes from the last approved package insert.

Recommendation:
An approval letter should issue for this supplement as set forth under 21 CFR 314.70 (b) (3) [Any change in labeling].

/S/ 2/6/01
Zelda McDonald, RHPM

cc: orig. NDA
HFD-110
HFD-110/McDonald
HFD-110/Blount
HF-2
DESCRIPTION

Toprol-XL, metoprolol succinate, is a beta₂-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended-release tablets. Toprol-XL has been formulated to provide a controlled and predictable release of metoprolol for once daily administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 23.75, 47.5, 95, and 190 mg of metoprolol succinate equivalent to 25, 50, 100 and 200 mg of metoprolol tartrate, USP, respectively. Its chemical name is (2S)-N-[2-(2-Dimethylaminoethoxy)ethyl]-N-methylmethanesulfonamide succinate (2:1) salt. Its structural formula is:

\[
\text{CH}_3\text{CH}_2\text{CH}_2\text{NHCH(CH}_3\text{)}_2\text{COOH} = \text{CH}_2\text{CH}_3\text{CH}_2\text{OCH}_3
\]

Metoprolol succinate is a white crystalline powder with a molecular weight of 652.8. It is freely soluble in water; soluble in methanol; sparingly soluble in ethanol; slightly soluble in dichloromethane and 2-propanol; practically insoluble in ethyl acetate, acetone, diethyl ether, and heptane. Inactive ingredients: silicon dioxide, cellulose compounds, sodium stearoyl lactate, polyethylene glycol, titanium dioxide, paraffin.

CLINICAL PHARMACOLOGY

General

Metoprolol is a beta₂-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta₁-adrenoceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.

Clinical pharmacology studies have confirmed the beta-blockade activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex ortosolic tachycardia.

The relative beta₂-selectivity of metoprolol has been confirmed by the following: (1) in normal subjects, metoprolol is unable to reverse the beta₂-mediated vasodilating effects of epinephrine. This contrasts with the effects of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. (2) In asthmatic patients, metoprolol reduces FEV₁ and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta₂-receptor blocking doses.

In five controlled studies in normal healthy subjects, the same daily doses of Toprol-XL and immediate-release metoprolol were compared in terms of the extent and duration of beta₂-blockade produced. Both formulations were given in a dose range equivalent to 100-400 mg of immediate-release metoprolol per day. In these studies, Toprol-XL was administered once a day and immediate-release metoprolol was administered once or twice a day. A such controlled study compared the
reduces FEV₁ and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta₁-receptor blocking doses. In five controlled studies in normal healthy subjects, the same daily doses of Toprol-XL and immediate release metoprolol were compared in terms of the extent and duration of beta₁-blockade produced. Both formulations were given in a dose range equivalent to 100-400 mg of immediate release metoprolol per day. In these studies, Toprol-XL was administered once daily and immediate release metoprolol was administered once or four times a day. A six controlled study compared the beta₁-blocking effects of a 50 mg daily dose of the two formulations. In each study, beta₁-blockade was expressed as the percent change from baseline in exercise heart rate following standardised submaximal exercise tolerance tests at steady state. Toprol-XL administered once a day and immediate release metoprolol administered once or four times a day provided comparable total beta₁-blockade over 24 hours (area under the beta₁-blockade versus time curve) in the dose range 100-400 mg. At a dosage of 50 mg once daily, Toprol-XL produced significantly higher total beta₁-blockade over 24 hours than immediate release metoprolol. For Toprol-XL, the percent reduction in exercise heart rate was relatively stable throughout the entire dosage interval and the level of beta₁-blockade increased with increasing doses from 50 to 300 mg daily. The effects at peak/trough (i.e., at 24 hours post dosing) were: 14%, 18%, 24%, 27% for 100, 200, 300 and 400 mg Toprol-XL once a day, respectively. In contrast to Toprol-XL, immediate release metoprolol given at a dose of 50-100 mg once daily produced a significantly larger peak effect on exercise tachycardia, but the effect was not evident at 24 hours. To match the peak to trough ratio obtained with Toprol-XL over the dosing range of 200 to 400 mg, a t.i.d. to q.i.d. divided dosing regimen was required for immediate release metoprolol. A controlled cross-over study in heart failure patients compared the plasma concentrations and beta₁-blocking effects of 50 mg immediate release metoprolol administered t.i.d., 100 mg and 200 mg Toprol-XL once daily. A 50 mg dose of immediate release metoprolol t.i.d. produced a peak plasma level of metoprolol similar to the peak level observed with 200 mg of Toprol-XL. A 200 mg dose of Toprol-XL produced a larger effect on suppression of exercised-induced and Holter-monitored heart rate over 24 hours compared to 50 mg t.i.d. of immediate release metoprolol.

The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmacological formulation. Using the E_{max} model, the maximal beta₁-blocking effect has been estimated to produce a 30% reduction in exercise heart rate. Beta₁-blocking effects in the range of 30-80% of the maximal effect (corresponding to approximately 8-23% reduction in exercise heart rate) are expected to occur at metoprolol plasma concentrations ranging from 3.5-400 ng/mL. The concentration-effect curve begins at a plateau between 200-300 ng/mL, and higher plasma levels produce little additional beta₁-blocking effect. The relative beta₂-selectivity of metoprolol diminishes and blockade of beta₂-adrenoceptors increases at higher plasma concentrations.

Using the E_{max} model, the maximal beta₁-blocking effect has been estimated to produce a 30% reduction in exercise heart rate. Beta₁-blocking effects in the range of 30-80% of the maximal effect (corresponding to approximately 8-23% reduction in exercise heart rate) are expected to occur at metoprolol plasma concentrations ranging from 3.5-400 ng/mL. The concentration-effect curve begins at a plateau between 200-300 ng/mL, and higher plasma levels produce little additional beta₁-blocking effect. The relative beta₂-selectivity of metoprolol diminishes and blockade of beta₂-adrenoceptors increases at higher plasma concentrations.

Although beta₁-adrenergic receptor blockade is useful in the treatment of angina, hypertension, and heart failure there are situations in which sympathetic stimulation is vital. In patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. In the presence of AV block, beta-blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta₂-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients.

In other studies, treatment with Toprol-XL produced an improvement in left ventricular ejection fraction. Toprol-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.

Hypertension

The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect reducing renal sympathetic outflow to the periphery; and (3) suppression of renin activity.

Clinical Trials

In controlled clinical studies, an immediate release dosage form of metoprolol has been shown to be an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics at dosages of 100-400 mg daily. Toprol-XL, in dosages of 100 to 400 mg once daily, has been shown to possess comparable beta₁-blockade as conventional metoprolol tablets administered two to four times daily. In addition, Toprol-XL administered at a dose of 50 mg once daily has been shown to reduce blood pressure 24-hours post-dosing in placebo controlled studies. In controlled, comparative, clinical studies, immediate release metoprolol appeared comparable as an antihypertensive agent to propranolol, methyldopa, and thiazide-type diuretics, and affected both supine and standing blood pressure. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to drug plasma concentration, selection of proper dosage requires individual titration.

Angina Pectoris

By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris.

Clinical Trials

In controlled clinical trials, an immediate release formulation of metoprolol has been shown to be an effective antianginal agent, reducing the number of angina attacks and increasing exercise tolerance. The dosage used in these studies ranged from 100 to 400 mg daily. Toprol-XL, in dosages of 100 to 400 mg once daily, has been shown to possess beta-blockade similar to conventional metoprolol tablets administered two to four times daily.

Heart Failure

The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.
metoprolol has been shown to be an effective antianginal agent, reducing the number of angina attacks and increasing exercise tolerance. The dosage used in these studies ranged from 100 to 600 mg daily. Toprol-XL in doses of 100 to 400 mg once daily, has been shown to possess beta-blockade similar to conventional metoprolol several times daily.

Heart Failure

The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.

Clinical Trials

MERIT-HF was a double-blind, placebo-controlled study of Toprol-XL, conducted in 14 countries including the U.S. It randomized 3931 patients [950 to Toprol-XL with 185 0.40 and NYHA Class II-V heart failure attributable to ischemia, hypertension, or cardiomyopathy. The protocol excluded patients with contraindications to beta-blocker use, those expected to undergo heart surgery, and those within 28 days of myocardial infarction or unstable angina. The primary endpoints of the trial were (1) all-cause mortality plus all-cause hospitalization time to first event, and (2) all-cause mortality. Patients were stabilized on optimal concomitant therapy for heart failure, including diuretics, ACE inhibitors, cardiac glycosides, and nitrates. At randomization, 49% of patients were NYHA Class II, 55% NYHA Class III: 57% of patients had heart failure attributed to ischemic heart disease; 49% had a history of hypertension; 26% had diabetes mellitus; and 46% had a history of myocardial infarction. Among patients in the trial, 99% were on diuretics, 89% were on ACE inhibitors, 84% were on digitals, 27% were on a lipid-lowering agent, 31% were on an oral anticoagulant, and the mean ejection fraction was 28%. The mean duration of follow-up was one year. At the end of the study, the mean daily dose of Toprol-XL was 159 mg.

The trial was terminated early for a statistically significant reduction in all-cause mortality (33% nominal p=0.0004). The risk of all-cause mortality plus all-cause hospitalization was reduced by 19% (p=0.00012). The trial also showed improvements in heart failure-related mortality and heart failure-related hospitalizations, and NYHA functional class.

The table below shows the principal results for the overall study population. The figure below illustrates principal results for a wide variety of subgroup comparisons, including US vs. non-US populations (the latter of which was not pre-specified). The combined endpoints of all-cause mortality plus all-cause hospitalization and of mortality plus heart failure hospitalization showed consistent effects in the overall study population and the subgroups, including women and the US population. However, in the US subgroup and women, overall mortality and cardiovascular mortality appeared less affected. Analyses of death and US patients were carried out because they each represented about 25% of the overall population. Nonetheless, subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.

<table>
<thead>
<tr>
<th>Clinical Endpoints in the MERIT-HF Study</th>
<th>Number of Patients</th>
<th>Relative Risk</th>
<th>Nominal P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Toprol-XL</td>
<td>(95% CI)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>All-cause mortality plus all-cause</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>hospitalization</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>All-cause mortality plus heart failure</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>hospitalization</td>
<td>1916</td>
<td>1915</td>
<td>0.91 (0.71-1.15)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>203</td>
<td>128</td>
<td>0.62 (0.51-1.02)</td>
</tr>
<tr>
<td>Sudden death</td>
<td>134</td>
<td>70</td>
<td>0.55 (0.31-0.99)</td>
</tr>
<tr>
<td>Death due to heart failure or hospital</td>
<td>58</td>
<td>33</td>
<td>0.61 (0.37-1.02)</td>
</tr>
<tr>
<td>ation due to heart failure</td>
<td>54</td>
<td>28</td>
<td>0.61 (0.37-1.02)</td>
</tr>
<tr>
<td>Hospitalization due to heart failure</td>
<td>451</td>
<td>317</td>
<td>0.91 (0.67-1.23)</td>
</tr>
<tr>
<td>Cardiovascular hospitalization</td>
<td>774</td>
<td>549</td>
<td>0.91 (0.67-1.23)</td>
</tr>
</tbody>
</table>

1 Time to the event
2 Comparison of treatment groups examines the number of hospitalizations
3 Relative risk and risk reduction are non-applicable.

Pharmacokinetics

In man, absorption of metoprolol is rapid and complete. Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration indicating about 50% first pass metabolism. Metoprolol crosses the blood-brain barrier and has been reported in the CSF in concent-
Pharmacokinetics

Metoprolol is rapidly and completely absorbed after oral administration. Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism. Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 19% of the simultaneous plasma concentration.

Plasma levels achieved are highly variable after oral administration. Only a small fraction of the drug (about 1%) is bound to human serum albumin. Metoprolol is a racemic mixture of R- and S-enantiomers, and is primarily metabolized by CYP2D6. When administered orally, it exhibits stereoselective metabolism that is dependent on the oxidation phenotype. Elimination mainly involves transformation in the liver, and the plasma half-life ranges from approximately 3 to 7 hours. Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta blocking activity. Following intravenous administration, the urinary recovery of unchanged drug is approximately 10%.

The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Consequently, no reduction in dosage is usually needed in patients with chronic renal failure.

Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Concomitant use of weakly drugs in poor metabolizers will increase blood levels of metoprolol several fold, decreasing metoprolol's cardioselectivity. (See PRECAUTIONS, Drug Interactions.)

In comparison to conventional metoprolol, the plasma metoprolol levels following administration of Toprol-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation. The peak plasma levels following once daily administration of Toprol-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses. At steady state the average bioavailability of metoprolol following administration of Toprol-XL, across the dosage range of 50 to 400 mg once daily was 77% relative to the corresponding single or divided doses of conventional metoprolol. Nevertheless, over the 24 hour dosing interval, B-blockade is comparable and dose-related (see CLINICAL PHARMACOLOGY). The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following Toprol-XL administration.

INDICATIONS AND USAGE

Hypertension
Toprol-XL is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Angina Pectoris
Toprol-XL is indicated in the long-term treatment of angina pectoris.

Heart Failure
Toprol-XL is indicated for the treatment of stable, symptomatic (NYHA Class I or II) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digoxin. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalization for heart failure.

CONTRAINDICATIONS
Toprol-XL is contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, and sick sinus syndrome (unless a permanent pacemaker is in place) (see WARNINGS).

WARNINGS

Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered Toprol-XL, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored if angina markedly worsens or acute coronary insufficiency develops. Toprol-XL administration should be reinitiated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue Toprol-XL therapy abruptly even in patients treated only for hypertension.

Bronchospastic Diseases: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1-selectivity, however, Toprol-XL may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since beta2-selectivity is not absolute, a beta2-stimulating agent should be administered concomitantly and the lowest possible dose of Toprol-XL should be used (see DOSAGE AND ADMINISTRATION).

Major Surgery: The necessity or desirability of withdrawing beta-blocker therapy prior to major surgery is controversial. The impaired

(continued on reverse side)
ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

Toprol-XL, like other beta-blockers, is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dibucaine or apranolol. However, such patients may be subject to prolonged severe hypotension. Difficulty in restarting and maintaining the heart beat has also been reported with beta-blockers.

Diabetes and Hypoglycemia: Toprol-XL should be used with caution in diabetic patients if a beta-blocking agent is required. Beta-blockers may mask lactic acidosis occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected.

Thyrotoxicosis: Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade, which might precipitate a thyroid storm.

PRECAUTIONS

General

Toprol-XL should be used with caution in patients with impaired hepatic function.

Worsening cardiac failure may occur during up-titration of Toprol-XL. If such symptoms occur, dosage should be increased and the dose of Toprol-XL should not be advanced until clinical stability is restored (see DOSAGE AND ADMINISTRATION). It may be necessary to lower the dose of Toprol-XL or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of Toprol-XL.

Information for Patients

Patients should be advised to take Toprol-XL regularly and continuously, as directed, preferably with or immediately following meals, if a dose should be missed, the patient should take the next scheduled dose (without doubling it). Patients should not interrupt or discontinue Toprol-XL without consulting the physician.

Patients should be advised (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with Toprol-XL has been determined; (2) to contact the physician if they difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking Toprol-XL.

Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.

Laboratory Tests

Clinical laboratory findings may include elevated levels of serum transaminase, alkaline phosphatase, and lactate dehydrogenase.

Drug Interactions

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with Toprol-XL plus a catecholamine depleter should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

Drugs that inhibit CYP2D6 such as quinidine, flecainide, propafenone, and sotalol are likely to increase metoprolol concentration. In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 300 mg and immediate-release metoprolol 200 mg, tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have been conducted to evaluate the carcinogenic potential of metoprolol tartrate. In 2-year studies in rats at three oral dosage levels of up to 800 mg/kg/day (41 times, on a mg/m² basis, the daily dose of 200 mg for a 60-kg patient), there was no evidence of tumorigenic properties at any of the dosage levels studied. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulations of foamy macrophages in pulmonary alveoli and a slight increase in bile duct hyperplasia, in a 21-month study in Swanes brown mice at three oral dosage levels of up to 150 mg/kg/day (18 times, on a mg/m² basis, the daily dose of 200 mg for a 60-kg patient), benign lung tumors (benign adenomas) occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total (benign plus malignant) lung tumors, nor in the overall incidence of tumors or malignant tumors. This 21-month study was repeated in CD-1 mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type of tumor.

Genotoxicity tests performed on metoprolol tartrate in a dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nuclear anomaly test in somatic mammalian tissue were negative. No evidence of impaired fertility due to metoprolol tartrate was observed in a study performed in rats at doses up to 22 times, on a mg/m² basis, the daily dose of 200 mg in a 60-kg patient.

Pregnancy Category C

Metoprolol tartrate has been shown to increase post-implantation loss and decrease neonatal survival in rats at doses up to 22 times, on a
Salmeterol/fluticasone (mucinolytic test) and a nucleolar
aromacy test in somatic interphase nuclei) and metoprolol succinate (a
Salmeterol/midazolam-mucinolytic test) were negative.
No evidence of impaired fertility due to metoprolol tartrate was
observed in a study performed in rats at doses up to 20 times, on a
mg/m² basis, the daily dose of 200 mg in a 60 kg patient.

Pregnancy Category C
Metoprolol tartrate has been shown to increase post-implantation loss
and decrease neonatal survival in rats at doses up to 22 times, on a
mg/m² basis, the daily dose of 200 mg in a 60 kg patient. Distribution
studies in mice confirm exposure of the fetus when metoprolol tartrate
is administered to the pregnant animal. These studies have revealed no
evidence of impaired fertility or teratogenicity. There are no adequate
and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, this
drug should be used during pregnancy only if clearly needed.

Nursing Mothers
Metoprolol is excreted in breast milk in very small quantities. An infant
consuming 1 liter of breast milk daily would receive a dose of less than
1 mg of the drug. Caution should be exercised when Toprol-XL is
administered to a nursing woman.

Pediatric Use
Safety and effectiveness in pediatric patients have not been estab-
lished.

Geriatric Use
Clinical studies of Toprol-XL in hypertension did not include sufficient
numbers of subjects aged 65 and over to determine whether they
respond differently from younger subjects. Other reported clinical
experience in hypertensive patients has not identified differences in
responses between elderly and younger patients.

Of the 1,990 patients with heart failure randomized to Toprol-XL in the
MERIT-HF trial, 50% (990) were 65 years of age and older and 12%
(238) were 75 years of age and older. There were no notable differences
in efficacy or the rate of adverse events between older and younger
patients.

In general, dosage selection for an elderly patient should be cautious,
usually starting at the low end of the dosing range, reflecting greater
frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy.

Risk of Anaphylactic Reactions
While taking beta blockers, patients with a history of severe
anaphylactic reactions to a variety of allergens may be more reactive to
repeated challenge, either accidental, diagnostic or therapeutic. Such
patients may be unresponsive to the usual doses of epinephrine used to
treat anergic reaction.

ADVERSE REACTIONS

Hypertension and Angina
Most adverse effects have been mild and transient. The following
adverse reactions have been reported for metoprolol tartrate.

Central Nervous System: Tiredness and dizziness have occurred in
about 1 of 100 patients. Depression has been reported to occur at 5
of 100 patients. Mental confusion and short-term memory loss have been
reported. Headache, somnolence, nightmares, and insomnia have also
been reported.

Cardiovascular: Shortness of breath and bradycardia have occurred in
approximately 3 of 100 patients. Cold extremities; arterial insuffi-
ciency; edema of the Raynaud type; palpitations; congestive heart
failure; peripheral edema; syncope; chest pain; and hypertension have
been reported in about 1 of 100 patients (see CONTRAINDICATIONS,
WARNINGS AND PRECAUTIONS).

Respiratory: Wheezing (bronchospasm) and dyspnea have been
reported in about 1 of 100 patients (see WARNINGS).

Gastrointestinal: Diarrhea has occurred in about 5 of 100 patients.
Nausea, dry mouth, gastric pain, constipation, flatulence, dyspeptic tract
disorders and heartburn have been reported in about 1 of 100 patients.

Hypersensitivity Reactions: Pruritus or rash have occurred in about
5 of 100 patients. Worsening of psoriasis has also been reported.

Miscellaneous: Peyronie's disease has been reported in fewer than
1 of 100,000 patients. Musculoskeletal pain, blurred vision, decreased
labor and truncus have also been reported.

There have been rare reports of reversible alopeia, agranulocytosis,
and dry eyes. Discontinuation of the drug should be considered if any
such reaction is not otherwise explicable. The ocu-lumussocutaneous
syndrome associated with the beta blocker propranolol has not been
reported with metoprolol.

Potential Adverse Reactions
A variety of adverse reactions not listed above have been reported with
other beta-adrenergic blocking agents and should be considered
potential adverse reactions to Toprol-XL.

Central Nervous System: Reversible mental depression progressing
to catatonia; an acute reversible syndrome characterized by disorien-
tation for time and place; short-term memory loss; emotional lability;
slightly clouded sensorium; and decreased performance on neuropsy-
chometric tests.

Hematologic: Agranulocytosis, nonthrombocytopenic purpura,
thrombocytopenic purpura.

Hypersensitive Reactions: Fever combined with itching and sore
throat, laryngospasm, and respiratory distress.

Heart Failure
In the MERIT-HF trial, serious adverse events and adverse events leading
to discontinuation of study medication were systematically collected. In
the MERIT-HF study comparing Toprol-XL in daily doses up to 200 mg mean
dose 1.9 mg once daily (n=1990) to placebo (n=200), 10.3% of Toprol-XL
patients discontinued for adverse events vs. 12.2% of placebo patients.
The table shows adverse events in the MERIT-HF study that occurred at
an incidence of equal to or greater than 1% in the Toprol-XL group and
greater than placebo by more than 0.5%, regardless of the assessment of
causality.

Adverse Events Occurring in the MERIT-HF Study at an Incidence ≥ 1%
in the Toprol-XL Group and Greater Than Placebo by More Than 0.5%
Adverse Events Occurring in the MERIT-HF Study at an Incidence > 1% in the Toprol-XL Group and Greater than Placebo by More Than 0.5%

<table>
<thead>
<tr>
<th></th>
<th>Toprol-XL</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness/vomiting</td>
<td>1.8</td>
<td>1.0</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>1.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Accidents and injury</td>
<td>1.5</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Other adverse events with an incidence > 1% on Toprol-XL and as common on placebo (within 0.5%) included myocardial infarction, pneumonia, cerebrovascular disorder, chest pain, dyspepsia/dyspepsia aggravated, syncope, coronary artery disease, ventricular arrhythmia, anemia, conduction disturbances, heart failure, hypotension, diabetes mellitus, edema, breast pain, abdominal pain, and fatigue.

OVERDOSE

Acute Toxicity

There have been a few reports of overdose with Toprol-XL and no specific overdose information was obtained with this drug. The exception is an animal toxicology study. However, since Toprol-XL (metoprolol succinate salt) contains the same active moeity, metoprolol, as conventional metoprolol tablets (metoprolol maleate salt), the recommendations on overdose for metoprolol conventional tablets are applicable to Toprol-XL.

Signs and Symptoms

Overdose of Toprol-XL may lead to severe hypotension, sinus bradycardia, asystole, ventricular tachycardias, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, impairment of consciousness/coma, nausea, vomiting, and cyanosis.

Treatment

In general, patients with acute or recent myocardial infarction or congestive heart failure may be more hemodynamic unstable than other patients and should be treated accordingly. When possible the patient should be treated under intensive care conditions. On the basis of the pharmacologic actions of metoprolol, the following general measures should be employed.

Elimination of the Drug: Gastric lavage should be performed. Bradycardia: Atropine should be administered. If there is no response to vagal blockade, isoproterenol should be administered cautiously. Hypotension: A vasoressor should be administered, e.g., levophedrine or dopamine. Bronchospasm: A beta-stimulating agent and/or a theophylline derivative should be administered. Cardiac Failure: A diuretics and diuretics should be administered. In shock resulting from inadequate cardiac contractility, administration ofdobutamine, isoproterenol or glucagon may be considered.

DOSEAGE AND ADMINISTRATION

Toprol-XL is an extended-release tablet intended for once-a-day administration. When switching from immediate release metoprolol tablets to Toprol-XL, the same total daily dose of Toprol-XL should be used. As with immediate release metoprolol, dosages of Toprol-XL should be individualized and titration may be needed in some patients. Toprol-XL tablets are scored and can be divided; however, the whole or half tablet should be swallowed whole and not chewed or crushed.

Hypotension

The usual initial dosage is 50 to 100 mg daily in a single dose, whether used alone or added to a diuretic. The dosage may be increased at weekly or longer intervals until optimum blood pressure reduction is achieved. In general, the maximum effect is reached 1 week after the dosage is increased. Dosages above 400 mg per day have not been studied.

Anxiety, Angina Pectoris

The dosage of Toprol-XL should be individualized. The usual initial dosage is 100 mg daily in a single dose. The dosage may be gradually increased at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate.

Hypertension

Dosage above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1-2 weeks (see WARNINGS).

Heart Failure

Dosage must be individualized and closely monitored during initiation. Prior to initiation of Toprol-XL, the dosing of diuretics, ACE inhibitors, and digitals (if used) should be stabilized. The recommended starting dose of Toprol-XL is 2.5 mg once daily for two weeks in patients with NYHA Class II heart failure and 12.5 mg once daily in patients with severe heart failure. The dose should be then titrated every two weeks to the highest dosage level tolerated by the patient or up to 250 mg of Toprol-XL. If transient worsening of heart failure occurs, it may be treated with increased doses of diuretics and it may also be necessary to lower the dose of Toprol-XL or temporarily discontinue it. The dose of Toprol-XL should not be increased until symptoms of worsening heart failure have been stabilized. Initial difficulty with titration should not preclude later attempts to introduce Toprol-XL. If heart failure patients experience symptomatic bradycardia, the dose of Toprol-XL should be reduced.

HOW SUPPLIED

Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, film-coated, and scored.
Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate. USP are white, biconvex, film-coated, and scored.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Shape</th>
<th>Engraving</th>
<th>NDC 0186-</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mg*</td>
<td>Oval</td>
<td>§</td>
<td>1088-05</td>
</tr>
<tr>
<td>50 mg</td>
<td>Round</td>
<td>A</td>
<td>1090-05</td>
</tr>
<tr>
<td>100 mg</td>
<td>Round</td>
<td>m/s</td>
<td>1092-05</td>
</tr>
<tr>
<td>200 mg</td>
<td>Oval</td>
<td>m/y</td>
<td>1094-05</td>
</tr>
</tbody>
</table>

* The 25 mg tablet is scored on both sides.

Score at 25°C (77°F). Excursions permitted to 15-30°C (59-86°F). (See USP Controlled Room Temperature.)

All trademarks are the property of the AstraZeneca group
© AstraZeneca 2001

Manufactured for: AstraZeneca LP
Wilmington, DE 19850
By: AstraZeneca AB
S-151 85 Södertälje, Sweden

Made in Sweden